Alfandari S, Cabaret P, Nguyen S, Descamps D, Vachée A, Cattoen C, Van Grunderbeeck N
Service de réanimation et maladies infectieuses, centre hospitalier Dron, 155, rue du Président-Coty, 59200 Tourcoing, France.
Réanimation polyvalente, centre hospitalier Saint-Philibert, rue du Grand-But, 59160 Lomme, France.
Med Mal Infect. 2016 Jun;46(4):194-9. doi: 10.1016/j.medmal.2016.03.004. Epub 2016 Apr 27.
We aimed to update the epidemiology of bacteremia and evaluate their management and short-term outcome.
We conducted a prospective multicenter survey from October to November 2011. Consecutive patients with at least one positive blood culture (BC) were included in the study. We evaluated the type and adequacy of empirical and documented antibiotic therapy, time to active antibiotic therapy, compliance with guidelines, and 10-day outcome.
A total of 23 public and private hospitals and 633 patients (493 true pathogens and 140 contaminants) were included in the study. Patients' wards were medicine (57%), surgery (19%), intensive care (14%), onco/hematology (3.7%), pediatrics (3.4%), infectious diseases (1.8%), and obstetrics (1.2%). Main pathogens were Escherichia coli (36%), Staphylococcus aureus (16%), coagulase-negative staphylococci, and Klebsiella sp. (8% each). A total of 43 (8.7%) multidrug-resistant strains were observed, including 26 extended-spectrum beta-lactamase strains and 15 methicillin-resistant S. aureus strains. An antibiotic active against the isolated pathogen was used in 74% of empirical and 96% of documented therapies. Median time between BC and administration of an active drug was 0.61 day. Empirical antibiotic therapies were protocol-compliant in 77% of cases. Few (4%) patients with contaminated BC received an antibiotic therapy (all inappropriate). Day-10 mortality was 12.1%, higher in patients presenting with severe sepsis or septic shock (22.5%) than in patients presenting with non-severe bacteremia (7.1%; P<0.0001).
The management of bacteremia seems satisfactory in these volunteer hospitals but bacteremia remains a severe infection.
我们旨在更新菌血症的流行病学情况,并评估其治疗及短期预后。
我们于2011年10月至11月进行了一项前瞻性多中心调查。纳入研究的患者为连续的至少有一次血培养(BC)阳性的患者。我们评估了经验性和已记录的抗生素治疗的类型及充分性、开始有效抗生素治疗的时间、对指南的遵循情况以及10天的预后。
该研究共纳入了23家公立和私立医院的633例患者(493例为真正的病原体感染,140例为污染物感染)。患者所在科室为内科(57%)、外科(19%)、重症监护室(14%)、肿瘤/血液科(3.7%)、儿科(3.4%)、传染病科(1.8%)和产科(1.2%)。主要病原体为大肠杆菌(36%)、金黄色葡萄球菌(16%)、凝固酶阴性葡萄球菌和克雷伯菌属(各占8%)。共观察到43株(8.7%)多重耐药菌株,包括26株超广谱β-内酰胺酶菌株和15株耐甲氧西林金黄色葡萄球菌菌株。74%的经验性治疗和96%的已记录治疗使用了对分离出的病原体有效的抗生素。血培养与使用有效药物之间的中位时间为0.61天。77%的病例经验性抗生素治疗符合方案。很少(4%)有血培养污染物感染的患者接受了抗生素治疗(均不恰当)。第10天的死亡率为12.1%,出现严重脓毒症或脓毒性休克的患者(22.5%)高于非严重菌血症患者(7.1%;P<0.0001)。
在这些志愿医院中,菌血症的治疗似乎令人满意,但菌血症仍然是一种严重感染。